Akoya Biosciences (AKYA): Debts to Book Capitalization
Akoya Biosciences (AKYA) synthesizes its own reagents, purchasing only basic optics and chips. Revenue is generated through the supply of spatial biology systems to R&D centers and institutes. Monitoring of borrowed funds relative to equity demonstrates current leverage, where the 0.00 mark reflects the latest data. Growth is driven by demand for PhenoCycler platforms, bringing the company closer to operating profit.
%20-%20Debt%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_AKYA_-_Akoya-Biosciences_-_Debt-to-Net-Assets "Akoya - AKYA Debt to Book Capitalization Ratio (period 07/04/2022 - 07/19/2025) | 👁️GURU.Markets👁️")
Summary analytical data breakdowns for akoyabio.com (AKYA)
To minimize credit risks, Akoya Biosciences (AKYA) must monitor the stability of its capital structure. This ratio compares total liabilities to the total value of assets minus liabilities. By analyzing the share of debt financing within the balance sheet capitalization, an investor determines the business's degree of dependence on borrowed funds. A decrease in this metric confirms strengthening solvency. For Akoya Biosciences, this is critical during prolonged equipment procurement cycles, ensuring the preservation of margins through available liquidity.